Citations

Clear

2358 citation(s) found for "Yu, Long".

Long term clinical performance and analytical robustness of the Lumipulse plasma p‐tau217 assay in routine clinical practice
Ashrafzadeh-Kian, Susan, Bornhorst, Joshua A. , Vanderboom, Patrick M. , Callison, Sarah, Algeciras-Schimnich, Alicia

Mayo Clinic

Alzheimer's & Dementia | September 29, 2026 | Volume: 22 | Issue: 10 | Pages: No page available

10.1002/alz.71887 | PMID 42805946 Get It

Abstract INTRODUCTION Plasma phosphorylated tau 217 (p‑tau217) immunoassays are increasingly being used to assess Alzheimer's disease (AD) pathology despite limited data affirming test reliability over time. METHODS Clinical performance of the Fujirebio Lumipulse G p‑tau217 assay was assessed in 744 Mayo Clinic patients presenting for evaluation of cognitive impairment between July 2024 and December 2025. Cerebrospinal fluid p‑tau181/amyloid beta 42 or amyloid positron emission tomography, within 1 year of p‐tau217 testing, were used as reference. Analytical robustness was evaluated by tracking result frequencies over time, conducting quality control checks, performing 10 lot‑to‑lot comparisons, and comparing two versions of reagents. RESULTS Diagnostic accuracy for detection of AD pathology was 93% (95% confidence interval 91–95) with 23% intermediate results. Reduced estimated glomerular filtration rate was associated with increased intermediate results among amyloid‐negative individuals. Result frequencies remained stable, average imprecision was 8%, and analytical bias between lots and version changes were ≤ 11%. DISCUSSION The findings support plasma p‐tau217 reliability in clinical practice for evaluation of cognitively impaired individuals.
Postmenopausal Status Is Associated With Increased Risk of Medial Meniscus Posterior Root Tears and Subsequent Arthroplasty
Panos, Joseph A. , Teubner, Lauren, Long, Kyndra , Tagliero, Adam , Nagelli, Christopher V , Krych, Aaron J , Teubner, Lauren , Tagliero, Adam J. , Hevesi, Mario , Saris, Daniël B.F. , Nagelli, Christopher V. , Krych, Aaron J.

Mayo Clinic

Arthroscopy | September 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/arj.70561 | PMID 42750098 Get It

Purpose To identify risk factors for medial meniscus posterior root tears (MMPRT) and arthroplasty‐free survival in postmenopausal women, while secondary objectives included analyzing menopause‐specific factors associated with MMPRT and defining risk factors for conversion to arthroplasty in patients with a confirmed MMPRT. Methods All patients at our institution with a diagnosed meniscal tear through December 2024 were identified. From this cohort, women with a menopausal diagnosis preceding their meniscal tear were matched one‐to‐one with men by age and body mass index. Imaging studies were reviewed to identify MMPRTs. Subsequent arthroplasty, Charlson Comorbidity Index, menopausal type (surgical or physiologic), hormone replacement therapy, bisphosphonate usage, and bone mineral density were recorded. Logistic and Cox regression were used to define risk factors for MMPRT and arthroplasty; survivorship was determined using Kaplan‐Meier analyses. Results The final cohort consisted of 1564 patients (n = 782 women) with a median age of 63 years, of which 244 patients (15.6%) had MMPRT. Age and female sex were associated with MMPRT. The presence of an MMPRT, female sex, body mass index, and Charlson Comorbidity Index were associated with arthroplasty. Among postmenopausal women, age at menopause, surgical menopause, hormone replacement therapy, and bone mineral density were associated with MMPRT. For patients with MMPRT, female sex was associated with arthroplasty. Ten‐year survivorship‐free from arthroplasty in patients with MMPRT was 53.5% for women and 78.4% for men ( P = .02). Conclusions Postmenopausal status, age, and hormone replacement therapy usage are risk factors for MMPRT. Compared with men, postmenopausal women with MMPRT exhibit reduced arthroplasty‐free survival, underscoring the need for targeted interventions. Level of Evidence Level III, retrospective comparative study.
Advances in the diagnosis and management of skin and soft tissue infections
Long, Brit, Yadav, Krishan, Rech, Megan A. , Gottlieb, Michael, Long, Brit , Gottlieb, Michael

Mayo Clinic

BMJ | September 11, 2026 | Volume: 394 | Issue: No issue available | Pages: e100580

10.1136/bmj-2026-100580 | PMID 42727947 Get It

Abstract Skin and soft tissues infections (SSTIs) are common conditions, affecting millions worldwide. SSTIs range from uncomplicated cellulitis to necrotizing fasciitis and can be divided into non-purulent and purulent forms. Non-purulent SSTI is most commonly associated with beta-haemolytic streptococci, while purulent SSTI is typically associated with Staphylococcus aureus . Cellulitis most commonly presents with acute warmth, pain, tenderness to palpation, erythema, and oedema. Skin abscess typically presents with a fluctuant tender area with erythema. Laboratory testing is of limited use in most patients. Point-of-care ultrasound is useful for distinguishing cellulitis from abscess if the diagnosis is unclear. Management of SSTI includes antibiotics such as penicillin VK, dicloxacillin, or a cephalosporin, while treatment for skin abscess includes incision and drainage, with antibiotics recommended in select patients. Patients should elevate the affected extremity when possible, and non-steroidal anti-inflammatory drugs may reduce pain and inflammation. The effectiveness of decolonization for patients with recurrent cellulitis or skin abscess is controversial. While most patients with cellulitis or skin abscess are appropriate for discharge with follow-up, patients with sepsis and those with challenges adhering to therapy, immunosuppression, or failed outpatient therapy should be referred to the emergency department. Novel antibiotics such as tedizolid, delafloxacin, omadacycline, and ceftaroline may be considered in select cases.
Beyond Binary PTEN Loss: Integrating Genomics, Long-Term Outcomes, and AI-Assisted Digital Pathology to Define Actionable PTEN Deficiency in Prostate Cancer.
Zarka, Jabra, Pessoa, Rodrigo Rodrigues , Gupta, Sounak , Chen, Eric, Greipp, Patricia, Orme, Jacob J., Karnes, R. Jeffrey, Cheville, John C. , Heath, Elisabeth, Zarka, Jabra , Greipp, Patricia T. , Childs, Daniel S. , Orme, Jacob J. , Karnes, R. Jeffrey

Mayo Clinic

International Journal of Cancer Care and Delivery | September 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.53876/001a.129758 Get It

Chromosome 1q Gain Defines a Plasma Cell–Dominant Adverse‐Risk Subtype in AL Amyloidosis With Inferior Long‐Term Survival
Hellou, Tamer , Gauto‐Mariotti, Estefania , Alnughmush, Ahmed , Baughn, Linda B. , Kapoor, Prashant , Zanwar, Saurabh , Suzuki, Shinichiro , Steinhardt, Maximilian , Packard, Daniel George , Kourelis, Taxiarchis , Hayman, Suzanne R. , Hwa, Yi L. , Fonder, A., Hobbs, Miriam, Warsame, Rahma, Abdallah, Nadine , Kyle, Robert A., Kumar, Shaji , Mariotti, Estefania Gauto , Steinhardt, Maximilian , Packard, Daniel G , Kourelis, Taxiarchis V, Buadi, Francis K , Dingli, David , Leung, Nelson , Hwa, Yi L , Cook, Joselle M , Binder, Moritz , Abdallah, Nadine H , Lin, Yi , Go, Ronald S , Rajkumar, S Vincent , Gonsalves, Wilson , Kumar, Shaji K , Gertz, Morie A , Dispenzieri, Angela , Muchtar, E , Baughn, Linda B , Hellou, Tamer , Buadi, Francis K. , Dingli, David , Leung, Nelson , Fonder, Amie , Hobbs, Miriam, Warsame, Rahma , Cook, Joselle , Binder, Moritz , Lin, Yi , Go, Ronald S. , Kyle, R., Rajkumar, S. Vincent , Gonsalves, Wilson I. , Gertz, Morie A. , Dispenzieri, Angela , Muchtar, Eli

Mayo Clinic

American Journal of Hematology | August 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/ajh.70484 | PMID 42638274 Get It

ABSTRACT The prognostic relevance of multiple myeloma (MM)‐defined high‐risk (HR) cytogenetic abnormalities in AL amyloidosis is incompletely defined. We retrospectively evaluated 517 newly diagnosed AL amyloidosis patients seen at Mayo Clinic between 2012 and 2021 who had baseline plasma cell FISH. HR cytogenetics were defined as t (4;14), t (14;16), t (14;20), del(17p), or 1q gain/amplification (+1q). HR abnormalities were identified in 151 patients (29%); +1q accounted for most HR cases (122/151, 81%). Compared with standard‐risk (SR), patients harboring +1q demonstrated a greater clonal disease burden, including higher dFLC and bone marrow plasma cells, greater intact immunoglobulin secretion, higher plasma cell proliferative index, and enrichment for modified SLiM‐CRAB features. Hematologic and organ response patterns of +1q patients were generally comparable to SR patients, whereas non‐1q HR patients had a higher proportion of early hematologic responses. Patients harboring +1q demonstrated significantly inferior overall survival (OS) compared with both non‐1q HR patients and SR patients (median OS 57 months vs. not reached vs. 120 months, p = 0.02). In multivariable piecewise Cox analysis, the adverse prognostic impact of +1q was most evident beyond 24 months from diagnosis (HR 2.89, 95% CI 1.64–5.09, p < 0.001), whereas non‐1q HR lesions were not independently prognostic. These findings suggest that +1q identifies a biologically distinct AL amyloidosis subset characterized by plasma cell–dominant features and inferior long‐term disease control. In contrast, other MM‐defined HR cytogenetic abnormalities appear to have limited prognostic relevance in AL amyloidosis.
T-cell immunosenescence limits CD19 CAR T-cell function in chronic lymphocytic leukemia
Noll, Julia Han , Dersh, Devin , Li, Jiang Yuan, Hemani, Humza , Lavorando, Maya, Bartoszek, Robert, Amses, Kevin R. , Jain, Ankita , Minehart, Janna , Shestov, Max A, Camerini, Elena , Loren, Alison W., Woyach, Jennifer A. , Goronzy, Jorg Josef, Kater, Arnon P. , Porter, David L., Bushman, Frederic D, Levine, Bruce L. , June, Carl H. , Long, Meixiao, Weng, Nan‐ping , Diorio, Caroline, Ramirez-Fernandez, Angel , Paruzzo, Luca , Camerini, Elena , Peters, Fleur S , Huang, Xiao , Woyach, Jennifer A , Kater, Arnon P , Ruella, Marco , Byrd, John C , Schuster, Stephen J , Siegel, Donald L , Levine, Bruce L , June, Carl H , Frey, Noelle V , Cohen, Adam D , Garfall, Alfred L , Long, Meixiao , Maus, Marcela V , Weng, Nan-Ping , Fraietta, Joseph A , Bartoszek, Robert L. , Ho, Matthew , Paruzzo, Luca , Shestov, Max, Loren, Alison W. , Goronzy, Jörg J. , Ruella, Marco , Byrd, John C. , Powell, Daniel J. , Gill, Saar , Porter, David L. , Schuster, Stephen J. , Bushman, Frederic D. , Frey, Noelle V. , Cohen, Adam D. , Garfall, Alfred L. , Diorio, Caroline J.

Mayo Clinic

Blood Journal | August 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/blood.2025032274 | PMID 42636161 Get It

CD19-directed CAR T-cells (CTL019) can produce durable remissions in chronic lymphocytic leukemia (CLL), but therapeutic success depends on whether autologous T-cells expand, persist, and retain cytotoxic function after manufacturing. Failure of CLL T-cells is often attributed to exhaustion, although many dysfunctional CLL T-cells retain inflammatory cytokine production. We tested whether this paradox reflects immunosenescence, an aging-like program defined by costimulatory loss, DNA damage, inflammatory secretion, repertoire restriction, and proliferative arrest. In response-linked preinfusion CTL019 products, nonresponders and short partial responders had higher senescence and senescence-associated secretory phenotype (SASP) programs than the functional-responder group, comprising complete responders and partial responders with transformed disease. These programs were detectable before infusion and became more prominent during manufacture in susceptible products. They tracked with weak in vivo CAR T-cell expansion and were associated with inferior survival. Serum proteomics revealed a circulating, CLL-associated SASP-like inflammatory milieu in nonresponders. Flow cytometry and T-cell receptor (TCR) profiling showed that poor responders carried CD27⁻CD28⁻ and KLRG1⁺ CD8 T-cells at apheresis, lower product CD27, and reduced product TCR diversity. Research-manufactured CAR T-cells from treatment-naïve CLL samples displayed the same state, most prominently in CD4 CAR T-cells, with SA-β-gal, p16, p53, DNA damage, depletion of less-differentiated states, and senescence-enriched transcriptomes. Under repeated CD19 stimulation, CLL-derived products reached a proliferative ceiling, and p53-high products lost cytotoxic reserve. Ibrutinib improved proliferative fitness, attenuated senescence-associated features and SASP output in paired patient and direct-exposure assays, and enhanced CAR T-cell expansion in an ibrutinib-resistant CLL model. Together, these data identify immunosenescence as a measurable and functionally consequential barrier to CAR T-cell efficacy in CLL and a candidate for therapeutic modulation.
Epidemiologic Study of Transfusion-Related Alpha-Gal Syndrome
Kaufman, Richard M., Hoen, Anne G., Khan, Jenna, Knudson, C. Michael, Romero, Andres E. Mindiola, Mo, Allison , Takanashi, Minoko , Collaborative, UPTICK Study Group; for the Biomedical Excellence for Safer Transfusion (BEST), Cardigan, Rebecca, Stanworth, Simon J., Commins, Scott P. , Scherer, Emily A., Davenport, Robertson D., Afraz, Sajjad, Andrews, Jennifer , Casey, John, Sullivan, Jensyn Cone , Cousins, Clara C. , Giorgi, Valeria De , Delaney, Meghan, DelBaugh, Regina M. , Gilstad, Colleen W. , Gofton, Alexander , Hill, Kate, Hogan, Keenan , Humbrecht, Catherine , Ikeda, Kazuhiko, Javanbakht, Ayda, Juskewitch, Justin E, Wojtowicz, Monique M. Menzies, Miller, Maureen J., Mills, Georgia, Nelson, Anna C. , Pauly, Marie C., Poisson, Jessica , Raval, Jay S., Samy, Nikitha, Sato, Tomohiko, Takeda, Yoshinori , Thibodeaux, Suzanne R. , Nunen, Sheryl van, Virk, Mrigender S., West-Mitchell, Kamille, Yamanouchi, Jun, Yoshihara, Satoshi, Zheng, X. Long, Ziman, Alyssa, Cone Sullivan, Jensyn , Kaufman, Richard Max , Hoen, Anne Gatewood , Knudson, Charles Michael , Metcalf, Ryan A. , Schäfer, Richard , Dunbar, Nancy M. , Cardigan, Rebecca A. , Stanworth, Simon J., Scherer, Emily A. , Cervinski, Mark A , Arai, Yasuyuki , Brugnara, Carlo , Allen, Elizabeth S. , Aurich, Konstanze , Casey, John , Cohn, Claudia S. , Crowe, Elizabeth P , Delaney, Meghan , Hendrickson, Jeanne E. , Hill, Kate, Ikeda, Kazuhiko , Jacquot, Cyril , Javanbakht, Ayda , Juskewitch, Justin E. , Lu, Wen , Wojtowicz, Monique Menzies , Miller, Maureen J. , Nelson, Anna , Pagano, Monica B. , Pauly, Marie-Christin , Saifee, Nabiha H , Sato, Tomohiko, Takeda, Yoshinori, Tiberghien, Pierre , Nunen, Sheryl van, Virk, Mrigender , Wood, Erica M , Yoshihara, Satoshi , Zheng, X. Long, Ziman, Alyssa

Mayo Clinic

JAMA Internal Medicine | August 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamainternmed.2026.3983 | PMID 42636004 Get It

Importance Recent case reports suggest that B antigen–containing blood products may be associated with anaphylactic transfusion reactions in recipients with preformed immunoglobulin E to galactose- α -1,3-galactose (alpha-gal). Objective To test the association of local alpha-gal syndrome (AGS) prevalence and allergic transfusion reaction (ATR) in patients with blood type O. Design, Setting, and Participants In this international, multicenter, retrospective cohort study at academic medical centers, sites were assigned to AGS high- or low-prevalence clusters based on the known geographic distribution of AGS. Data were collected on platelet or plasma transfusions and ATRs during 2020 to 2024. Consecutive patients receiving platelet or plasma transfusions were included. Exposures Patients with blood type O who received B or AB units and patients with blood type O who received O units (reference group) in AGS high- and low-prevalence clusters were compared. Main Outcomes and Measures Before data collection, the hypothesis was that if transfusion-related alpha-gal syndrome (TRAGS) is a true clinical entity, excess ATRs to group B or AB units would be detected in AGS high-prevalence regions exclusively. The main measure was the overall risk ratio (RR) for ATRs to B or AB plasma or platelets in AGS high- vs low-prevalence clusters. Results In total, 558 823 platelet and plasma transfusions at 40 sites in 5 countries were analyzed, of which ATRs occurred in 1744 transfusions (0.3%). In the US AGS high-prevalence cluster (9 sites), significantly more ATRs of any severity occurred among patients with blood type O who received B or AB units vs patients with blood type O who received O units (overall RR, 3.93; 95% CI, 2.96-5.21; P &amp;lt; .001). In contrast, in the primary analysis of the AGS low-prevalence cluster (15 sites), excess ATRs to B or AB units were not detected. In subgroup analyses among patients with blood type O receiving B units, the RR for moderate to severe ATRs was 9.14 (95% CI, 5.39-15.52; P &amp;lt; .001) in the AGS high-prevalence cluster vs 2.15 (95% CI, 1.34-3.47; P = .002) in the AGS low-prevalence cluster. Outside the US, a signal consistent with TRAGS was not detected. Conclusions and Relevance This cohort study provides provocative epidemiologic evidence that TRAGS may be a unique manifestation of AGS and a previously unrecognized risk associated with transfusion. In AGS high-prevalence regions, blood collectors and hospital transfusion services should consider approaches to preventing severe ATRs from B or AB plasma or platelet units.
Performance of general-population breast cancer risk prediction models in an international consortium
Brantley, Kristen D. , Ahearn, Thomas U, Norton, Emily , MacInnis, Robert, Palmer, Julie R, Vachon, Celine M, Beane-Freeman, Laura, Frost, Reuben, Zirpoli, Gary, Neuhouser, Marian L, Barnett, Matthew, Teras, Lauren R, Patel, Alpa V, Bodelon, Clara, Spielfogel, Emma S. , Kirsh, Victoria A. , Langseth, Hilde , Milne, Roger L, Haiman, Christopher, Scott, Christopher G, Eliassen, A. Heather, Rosner, Bernard, Willett, Walter C, Chen, Yu, Wu, Fen , Zheng, Wei, Long, Jirong, O'Brien, Katie M, Sandler, Dale P, Linet, Martha S. , Anderson, Garnet, Larson, Joseph C. , Lee, I-Min, Chatterjee, Nilanjan, Kraft, Peter, Brantley, Kristen D , Kirsh, Victoria A , Ahearn, Thomas U. , Norton, Emily L., Palmer, Julie R. , Fortner, Renée T. , Vachon, Celine M. , González, Amy Berrington de , Bertrand, Kimberly A. , Zirpoli, Gary , Barnett, Matthew J , Teras, Lauren R. , Hodge, James M. , Patel, Alpa V , Bodelón, Clara , Lacey, James V. , Rohan, Thomas E. , Tsuruda, Kaitlyn M. , Milne, Roger L , Rosner, Bernard, Willett, Walter C. , Romanos-Nanclares, Andrea , Zheng, Wei , Long, Jirong, O’Brien, Katie M. , Sandler, Dale P. , Kitahara, Cari M. , Anderson, Garnet L. , Lee, I-Min, García‐Closas, Montserrat , Chatterjee, Nilanjan

Mayo Clinic

No container title available | August 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.08.20.26360899 Get It

Background: Several breast cancer (BC) risk prediction models have been developed to provide personal risk assessments. Though individually validated, their performance has not been systematically evaluated across a wide range of populations or ages. Methods: We harmonized individual-level baseline questionnaire data and incident BC diagnoses from 21 cohorts from North America, Europe, and Australia participating in the Breast Cancer Risk Prediction Project. Five-year absolute risk of invasive BC was estimated for five established risk prediction models using classical risk factors only. Discrimination was evaluated by area under the curve (AUC). Calibration was assessed using average and risk-decile specific expected to observed (E/O) ratios. Performance metrics were meta-analyzed across cohorts and models. Metaregression tested associations between cohort characteristics and performance metrics. Results: This analysis included 1,595,977 women aged 20-75 years, enrolled in studies between 1976-2015, with 19,062 (1.2%) invasive BC cases ascertained within 5 years from exposure assessment. Age-adjusted AUCs were similar across models and cohorts (pooled AUCs by model: 0.57-0.58), while E/O ratios varied substantially (pooled E/O ratios by model: 0.83-1.25). Overestimation was common among predicted high-risk individuals (>3%). No appreciable differences in model performance by cohort age, birth year, race, and variable missingness emerged. Calibration improved after assigning race-specific incidence rates. Conclusion: Existing BC risk prediction models provided similar risk discrimination across multiple cohorts, although there was overestimation of risk for high-risk individuals. Performance variation across cohorts was not driven by specific characteristics, which supports development of a unified risk model for diverse populations that leverages appropriate incidence rates.
Ultrasound‐Guided Fasciotomy for Chronic Exertional Compartment Syndrome: A Case Report With Long‐Term Sonographic Outcomes
Lavigne, Alexandre , Boettcher, Brennan J. , Khadavi, Michael

Mayo Clinic

Journal of Clinical Ultrasound | August 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/jcu.70385 | PMID 42619030 Get It

ABSTRACT We report the case of a 38‐year‐old recreational female runner with anterior and lateral chronic exertional compartment syndrome treated with ultrasound‐guided fasciotomy using a V‐shaped meniscotome. She began her return‐to‐run protocol 8 days postprocedure and achieved full symptom resolution. At 6 months, ultrasound revealed persistent fascial separation without complications, representing the first report of long‐term sonographic outcomes following fasciotomy for chronic exertional compartment syndrome. These findings support further prospective studies to evaluate the clinical and sonographic outcomes of this technique.